Anti-Müllerian Hormone: The Biomarker of Ovarian Reserve

Anti-Müllerian hormone stands as one of the most transformative biomarkers in modern reproductive endocrinology, developmental biology, and clinical gynecology. By offering an unprecedented, non-invasive window into the primordial follicular pool of the human ovary as well as serving as a foundational determinant of embryonic sexual differentiation, this glycoprotein has fundamentally reshaped clinical protocols ranging from assisted reproductive technology to pediatric intersex diagnostics. Understanding its molecular dynamics, physiological mechanisms, and clinical limitations is essential for clinicians, researchers, and patients navigating the complex terrain of human fertility and reproductive health.

Anti-Müllerian Hormone (AMH)

1. Concise Definition

Anti-Müllerian hormone (AMH), also designated as Müllerian-inhibiting substance (MIS), is a dimeric glycoprotein belonging to the transforming growth factor-beta (transforming growth factor-beta) superfamily. In human embryogenesis, it is synthesized by the Sertoli cells of male fetal testes to induce the regression of the paramesonephric (Müllerian) ducts, thereby preventing the development of female internal reproductive structures. In postnatal females, AMH is produced exclusively by the granulosa cells of preantral and small antral ovarian follicles, functioning as a primary paracrine regulator of folliculogenesis and an established clinical surrogate for the quantitative ovarian reserve.

Beyond its binary role in fetal sex differentiation, AMH exerts persistent inhibitory actions in the adult female reproductive axis. Specifically, it inhibits the initial recruitment of primordial follicles from the quiescent resting pool into the growing cohort and attenuates the sensitivity of growing follicles to follicle-stimulating hormone (FSH) during cyclic selection. Because circulating serum concentrations of AMH reflect the continuous, gonadotropin-independent microenvironment of early follicular development, systemic AMH levels remain relatively stable across the natural menstrual cycle, rendering it a uniquely reliable endocrine metric.

2. Etymology & Linguistic Origin

The nomenclature of anti-Müllerian hormone derives from anatomical eponymy and functional pharmacology. The prefix anti- originates from the Ancient Greek ἀντί (antí), signifying “against,” “counter,” or “opposing.” The eponym Müllerian commemorates Johannes Peter Müller (1801–1858), a renowned German physiologist, comparative anatomist, and pioneer of cell theory who definitively described the embryonic paramesonephric ducts in his 1830 treatise on the structural origins of the internal sex organs.

The constituent term hormone was coined in 1905 by English physiologist Ernest Henry Starling, derived from the Ancient Greek present participle ὁρμῶν (hormôn), meaning “setting in motion” or “to urge on.” Consequently, the compound term anti-Müllerian hormone literally denotes a biochemical agent that actively counteracts or dismantles the embryonic Müllerian system. In earlier biochemical literature, primarily originating in North American research laboratories, the peptide was frequently cataloged as Müllerian-inhibiting substance (MIS) or Müllerian-inhibiting factor (MIF), designations that remain technically synonymous within contemporary endocrinology.

3. Pronunciation & Grammatical Form

In standard English phonetics, the term is pronounced as follows:

• anti-Müllerian: /ˌæn.ti.mʊˈlɪər.i.ən/ or /ˌæn.taɪ.mʊˈlɪər.i.ən/
• hormone: /ˈhɔːr.moʊn/
• Abbreviation (AMH): /ˌeɪ.ɛmˈeɪtʃ/

Grammatically, anti-Müllerian hormone operates as a compound non-count (mass) concrete noun within biomedical discourse (e.g., “Circulating anti-Müllerian hormone decreases progressively with chronological senescence”). When functioning as a premodifying descriptor, it behaves as an adjectival noun adjunct (e.g., “AMH signaling cascade,” “AMH receptor type II genetic polymorphisms”). The abbreviation “AMH” is universally treated as an initialism requiring the indefinite article “an” in speech and writing (e.g., “an AMH test”).

4. Detailed Conceptual Explanation

To conceptualize the physiological significance of anti-Müllerian hormone, one must analyze its divergent functions across biological sex, embryonic morphogenesis, and adult gametogenesis. During early vertebrate development, mammalian embryos are sexually bipotential, bearing both mesonephric (Wolffian) and paramesonephric (Müllerian) ductal systems. In genetic males possessing the SRY gene on the Y chromosome, testes differentiate and immature Sertoli cells begin robust transcription and translation of AMH between the 7th and 8th weeks of gestation. The secreted ligand engages specific cell-surface receptors on the adjacent Müllerian mesenchyme, initiating an apoptotic intracellular cascade that dissolves the ducts. Without AMH, the Müllerian ducts autonomously differentiate into the fallopian tubes, uterus, cervix, and the upper third of the vagina, as typically occurs in genetic females who lack early embryonic testicular AMH production.

In females, AMH production commences only late in gestation—detectable in fetal ovaries around week 36—and accelerates postnatally, reaching its biological apex during early adulthood (ages 20–25). Produced strictly by the granulosa cells of primary, secondary, and early antral follicles (measuring less than 8 to 10 millimeters in diameter), AMH serves as an essential gatekeeper of female reproductive pacing. Primordial follicles represent a non-renewable bank of immature oocytes arrested in the prophase of meiosis I. If all primordial follicles were simultaneously recruited, the ovarian reserve would rapidly deplete, resulting in premature reproductive exhaustion. AMH serves as the physiological brake on this process, directly dampening the rate of initial primordial emergence.

Once follicles initiate growth and acquire responsiveness to exogenous gonadotropins, AMH exerts a second inhibitory checkpoints by decreasing follicular sensitivity to circulating follicle-stimulating hormone (FSH). By attenuating FSH receptor responsiveness and downregulating aromatase gene expression, AMH prevents premature hyper-responsiveness to cyclic gonadotropins. Only when a selected dominant follicle surpasses 8–10 mm does AMH expression cease entirely, allowing the selected follicle to utilize FSH uninhibitedly, complete aromatization of androgens into estrogens, and proceed to ovulation under the influence of the luteinizing hormone (LH) surge.

Because granulosa cells terminate AMH secretion once a follicle becomes dominant or atretic, circulating peripheral serum levels do not reflect the dominant follicle or the corpus luteum. Rather, circulating AMH mirrors the cumulative baseline volume of the microscopic preantral and small antral follicular cohort. Because this active micro-cohort is directly proportional to the total remaining resting primordial pool, serum AMH provides an indirect, highly consistent quantitative estimate of the functional ovarian reserve across the human female reproductive lifespan.

5. Historical Development

The empirical journey uncovering anti-Müllerian hormone represents an iconic convergence of developmental biology, experimental microsurgery, and clinical endocrinology:

• 1947: Alfred Jost, a French endocrinologist and pioneering embryologist at the University of Paris, performed seminal microsurgical experiments on rabbit fetuses. Jost demonstrated that surgically removing fetal testes prior to somatic sex differentiation resulted in all embryos developing phenotypic female internal anatomy. Furthermore, grafting crystalline testosterone into castrated male embryos failed to induce Müllerian regression, proving that an uncharacterized, non-androgenic testicular secretion—which he termed “Müllerian inhibitor”—was responsible for actively dismantling the female reproductive tract.
• 1970s: Nathalie Josso and her research group in Paris, alongside Patricia K. Donahoe at Massachusetts General Hospital, successfully isolated, purified, and characterized the biochemical structure of bovine and human Müllerian-inhibiting substance, confirming it to be a high-molecular-weight glycoprotein.
• 1986: The human gene encoding AMH was cloned and mapped to the short arm of chromosome 19 (19p13.3) by Richard L. Cate and colleagues, ushering in the molecular era of research into transforming growth factor superfamily signaling pathways.
• 1990: The first quantitative enzyme-linked immunosorbent assays (ELISA) were introduced to measure AMH in human biological fluids, initially serving as diagnostic tools to detect persistent Müllerian duct syndrome, cryptorchidism, and granulosa cell tumors.
• 2002: Frank J. Broekmans, Bart C.J.M. Fauser, and their contemporaries published landmark clinical studies establishing that systemic concentrations of AMH correlate with chronological age, antral follicle counts, and oocyte yield during controlled ovarian hyperstimulation for in vitro fertilization (IVF), establishing AMH as the preeminent biomarker of ovarian reserve.
• 2010s–Present: The evolution from manual, variable microtiter plate assays to fully automated, highly sensitive chemiluminescent platforms (e.g., Roche Elecsys, Beckman Coulter Access) revolutionized reproducibility, allowing international endocrinological standardization and incorporation into diagnostic algorithms for polycystic ovary syndrome (PCOS).

6. Theoretical Foundations

The molecular mechanisms of AMH are governed by the principles of transforming growth factor-beta (TGF-β) receptor superfamily signaling. Like other members of this evolutionary family, AMH translates extracellular peptide interactions into altered nuclear gene transcription through specialized heteromeric serine/threonine kinase receptor complexes.

The biological processing of AMH involves an intricate proteolysis step. Translated as a 140-kDa homodimeric precursor protein, AMH contains an N-terminal pro-region and a smaller C-terminal mature domain. Physiological activation requires specific enzymatic cleavage between these domains by subtilisin-like proprotein convertases. Intriguingly, the cleaved N-terminal and C-terminal fragments remain non-covalently associated in an active complex; isolation of the C-terminal dimer alone displays significantly attenuated bioactivity, indicating that the pro-region is critical for optimal receptor binding and folding stability.

Signal transduction occurs through a designated dual-receptor architecture:

• Anti-Müllerian Hormone Receptor Type II (AMHR2): This primary transmembrane receptor binds the AMH ligand with exceptional specificity. AMHR2 expression is tightly localized to target tissues: fetal Müllerian duct mesenchyme, testicular Sertoli and Leydig cells, and ovarian granulosa cells.
• Type I Receptor Transphosphorylation: Upon ligand binding, AMHR2 recruits and transphosphorylates a partner Type I receptor serine/threonine kinase, primarily ALK2 (ACVR1), ALK3 (BMPR1A), or ALK6 (BMPR1B).
• SMAD Pathway Activation: The activated Type I receptor kinase directly phosphorylates intracellular receptor-regulated Smad proteins (R-SMADs), specifically SMAD1, SMAD5, and SMAD8. These phosphorylated R-SMADs bind the common mediator SMAD4, forming a heterotrimeric transcriptional complex that translocates into the nucleus to repress or activate target genes, including aromatase (CYP19A1) and gonadotropin receptor genes.

7. Key Components, Types & Dimensions

To evaluate AMH fully, one must delineate its structural biochemistry, functional dimensions, and pathological phenotypes:

• Biochemical Fractions:
  • Pro-AMH (Cleaved Precursor): The latent, uncleaved homodimer synthesized by granulosa and Sertoli cells, measuring roughly 140 kDa.
  • AMH_N,C Complex: The physiologically active, cleaved form composed of two 57-kDa N-terminal domains non-covalently bound to a 25-kDa C-terminal dimer, circulating systemically in human peripheral blood.
  • C-Terminal Dimer: The isolated receptor-binding fragment which, in the absence of the N-terminal component, possesses negligible structural stability and minimal in vivo potency.
• Physiological Dimensions Across the Lifespan:
  • Embryonic/Fetal Window: Robust testicular expression in males directing internal anatomical sculpting; absolute quiescence in females.
  • Childhood/Pubertal Transition: Male levels remain elevated throughout infancy before declining precipitously at puberty under the suppressive influence of intratesticular testosterone. Female levels remain minimal in early infancy, steadily climb during childhood, and peak at approximately 20 to 25 years of age.
  • Reproductive Adulthood: Steady, age-dependent female decline reflecting the continuous attrition of the quiescent ovarian follicular pool.
  • Menopausal Senescence: Undetectable or near-zero serum concentrations signifying functional depletion of follicles.
• Pathophysiological Extremes:
  • Persistent Müllerian Duct Syndrome (PMDS): A rare 46,XY condition caused by mutations in the AMH gene (Type I PMDS) or the AMHR2 gene (Type II PMDS), where phenotypic males exhibit retained bilateral fallopian tubes and a uterus.
  • Functional Ovarian Hyperstimulation Risk: Markedly elevated concentrations observed in individuals with polycystic ovary morphology, directly correlating with clinical susceptibility to ovarian hyperstimulation syndrome (OHSS).

8. Examples & Illustrative Cases

The practical behavior of AMH is best observed across distinct clinical scenarios reflecting varied reproductive, endocrine, and developmental circumstances:

Case 1: Controlled Ovarian Hyperstimulation in Assisted Reproduction

A 33-year-old female presents for fertility counseling following two years of unexplained subfertility. Comprehensive baseline profiling reveals an AMH serum concentration of 3.8 ng/mL (median expected: 1.5–2.5 ng/mL) and a bilateral antral follicle count (AFC) of 22. In response to this high-normal ovarian reserve parameter, the reproductive endocrinologist selects an individualized low-dose antagonist protocol (150 IU recombinant FSH daily) coupled with a GnRH-agonist trigger rather than human chorionic gonadotropin (hCG). This precise stratification minimizes the patient’s risk of developing ovarian hyperstimulation syndrome (OHSS) while safely retrieving 14 mature metaphase-II oocytes, culminating in a successful elective single-embryo transfer.

Case 2: Primary Ovarian Insufficiency (POI) in a Young Adult

A 27-year-old female presents with secondary amenorrhea lasting six months, accompanied by episodic vasomotor hot flashes and sleep fragmentation. Quantitative endocrine testing indicates an elevated serum FSH level of 54 IU/L, an estradiol reading below 20 pg/mL, and an undetectable AMH concentration (< 0.01 ng/mL). Repeat testing three months later confirms identical values. The suppressed AMH level indicates premature exhaustion of the resting primordial ovarian follicle reserve, confirming a diagnosis of primary ovarian insufficiency. The patient is transitioned to physiological hormone replacement therapy (HRT) for bone and cardiovascular protection, with oocyte donation discussed as the primary path to biological parenthood.

Case 3: Investigation of Ambiguous Genitalia in a Neonate

A newborn presents with ambiguous external genitalia, non-palpable bilateral gonads, and a 46,XY karyotype. Clinical investigators must urgently discern between gonadal dysgenesis, testosterone biosynthesis defects, and receptor insensitivity syndromes. A blood sample reveals serum AMH concentrations in the high male reference range. This confirms the presence of functional, viable Sertoli cells capable of initiating Müllerian regression, effectively ruling out complete bilateral gonadal dysgenesis and pointing the clinical investigation toward isolated androgen biosynthetic defects or androgen insensitivity syndrome.

9. Measurement & Assessment

Assaying human serum AMH requires rigorous bioanalytical techniques, as past analytical variations contributed to widespread confusion regarding universal reference thresholds:

• First-Generation Assays: Early enzyme-linked immunosorbent assays (e.g., the original Beckman Coulter DSL and Immunotech assays) relied on distinct antibodies recognizing different epitopes, producing discrepant results when quantifying the same serum sample.
• Second-Generation Assays: The convergence into the Beckman Coulter AMH Gen II assay in 2010 standardized the monoclonal antibody pairs, yet issues with complement component interference (C1q binding) occasionally led to unpredictable sample instability and required pre-dilution modifications.
• Automated Chemiluminescent Assays: Contemporary clinical practice relies heavily on fully automated, microparticle-based chemiluminescent immunoassay (CLIA) platforms, such as the Roche Elecsys AMH and the Beckman Coulter Access AMH platforms. These systems provide rapid turn-around times, limit of detection (LoD) levels as low as 0.01 ng/mL, and within-run coefficients of variation (CV) beneath 3%.
• Clinical Units of Measurement: AMH is reported globally in either nanograms per milliliter (ng/mL) or picomoles per liter (pmol/L). The conversion factor between the two metric frameworks is:$$ext{pmol/L} = ext{ng/mL} imes 7.14$$$$ext{ng/mL} = rac{ ext{pmol/L}}{7.14}$$
• Testing Modality and Biological Variation: Unlike FSH, estradiol, or progesterone, AMH demonstrates minimal fluctuation across the follicular and luteal phases of the human menstrual cycle. Consequently, blood draws can be performed on any cycle day. Nevertheless, minor intracycle variability (up to 10–15%) can occur, particularly in younger individuals with high follicular reserves. Long-term oral contraceptive usage, pregnancy, systemic critical illness, and significant vitamin D deficiency can transiently suppress circulating AMH levels by 20–30%, necessitating careful clinical contextualization.

10. Applications & Practical Significance

The clinical applicability of AMH spans diverse medical specialties, establishing it as an indispensable diagnostic and prognostic instrument:

• Assisted Reproductive Technology (ART): AMH testing is universally utilized to forecast the quantitative yield of oocytes following controlled ovarian hyperstimulation. Rather than functioning as a direct predictor of clinical pregnancy or live birth, AMH serves as an established dosing guide, allowing clinicians to tailor exogenous gonadotropin dosages to avoid cycle cancellations from poor responses (< 4 oocytes) or catastrophic complications from hyper-responses (> 15–20 oocytes).
• Evaluation of Polycystic Ovary Syndrome (PCOS): In females afflicted with PCOS, the massive pool of arrested preantral and small antral follicles produces excessive AMH, resulting in serum concentrations two to four times higher than in age-matched control subjects. Elevated AMH contributes directly to anovulation by blocking FSH-induced follicular maturation. The 2023 International Evidence-Based Guidelines for PCOS formally recognized automated AMH measurement as an acceptable, objective diagnostic alternative to transvaginal ultrasonographic assessment of polycystic ovarian morphology (PCOM).
• Oncofertility and Ovarian Toxicity Profiling: Women diagnosed with malignancies requiring gonadotoxic chemotherapy or pelvic radiation undergo baseline and longitudinal AMH testing to assess post-treatment reproductive potential, guide urgent pre-treatment cryopreservation of oocytes or ovarian tissue, and track follicular preservation.
• Surveillance of Granulosa Cell Tumors: Juvenile and adult granulosa cell tumors account for roughly 2–5% of ovarian neoplasms and secrete vast quantities of AMH. Serum levels act as a sensitive circulating tumor marker, providing oncologists with a reliable metric for post-resection disease surveillance and early detection of recurrent disease.
• Pediatric Intersex Diagnostics: In neonates and children presenting with disorders of sex development (DSD), cryptorchidism, or micropenis, AMH quantification rapidly differentiates between functional testicular tissue (elevated levels) and complete anorchia or gonadal agenesis (undetectable levels).

11. Research & Empirical Evidence

Extensive clinical and basic science investigations have solidified our understanding of AMH biology, while also dismantling several pervasive early clinical assumptions:

Seminal investigations led by Broekmans et al. (2006) and Nelson et al. (2012) definitively established the mathematical association between declining serum AMH concentrations and biological age, establishing the modern standard for age-stratified reference nomograms. These studies demonstrated that the median concentration of AMH falls progressively from its early adulthood peak until reaching an assay-undetectable threshold roughly five years prior to the biological onset of menopause.

Critically, large multicenter prospective trials, most notably the work by Steiner et al. (2017) published in the Journal of the American Medical Association (JAMA), investigated whether low AMH values in women of reproductive age predicted natural fecundability (the per-cycle probability of natural conception). The study prospectively tracked 750 women aged 30 to 44 years attempting to conceive naturally without fertility medications. The results demonstrated that individuals with depleted AMH concentrations (< 0.7 ng/mL) had identical cumulative probabilities of pregnancy over 6 and 12 cycles compared to women with normal AMH values. This study decisively proved that AMH is a metric of follicular quantity, not oocyte quality; in unassisted conception, a single healthy, developmentally competent oocyte can be selected and ovulated regardless of how few resting follicles remain in the ovarian bank.

Subsequent mechanistic work by Dewailly et al. (2014) mapped the pathogenetic role of AMH in polycystic ovary syndrome, showing that elevated systemic and local AMH drives hypothalamic dysregulation. Emerging preclinical research by Tata et al. (2018) published in Nature Medicine revealed that excess prenatal AMH exposure can cross the placental barrier, reprogram maternal and fetal neuroendocrine circuits, hyperactivate central GnRH neurons, and induce transgenerational transmission of neuroendocrine and reproductive PCOS phenotypes.

12. Cultural & Cross-Cultural Considerations

The transition of AMH from an inpatient academic hospital assay to a commercialized, direct-to-consumer laboratory test has created unique sociocultural phenomena globally. In modern industrialized societies characterized by socioeconomic pressures that delay childbearing, AMH has frequently been commercialized by diagnostic startups and mainstream media as a colloquial “fertility test” or an “egg timer.” This commercial recontextualization has induced widespread, non-evidence-based psychological distress among young women who discover low baseline AMH levels and mistakenly conflate reduced ovarian reserve with acute, immediate clinical sterility.

Conversely, in numerous cultures where female social status and marital stability are directly linked to fertility, low AMH values are sometimes interpreted as a source of familial stigma. This can prompt patients to seek costly, unregulated reproductive interventions, including unproven intra-ovarian platelet-rich plasma (PRP) injections or unindicated in vitro fertilization procedures. Cross-cultural bioethical guidelines emphasize the absolute clinical necessity of pre-test and post-test counseling, reminding patients that an AMH reading should never be interpreted as an absolute determinant of spontaneous conception, but rather as an endocrine parameter intended to guide specific medical decisions.

13. Criticisms, Debates & Limitations

The clinical and operational deployment of AMH is characterized by several ongoing controversies and physiological constraints:

• Poor Prognostic Value for Natural Conception: A continuous debate in reproductive medicine centers on the misapplication of AMH screening in healthy, nulliparous women who have not attempted spontaneous conception. Expert clinical bodies, including the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Reproductive Medicine (ASRM), explicitly advise against routine, unprompted screening of the general population due to its inability to predict spontaneous pregnancy success, leading to unnecessary medicalization and emotional distress.
• Oocyte Quality vs. Quantity: AMH reflects cellular volume within early follicular stages, offering no direct insight into the chromosomal normality (euploidy) or developmental competence of individual oocytes. A 26-year-old female with an exceptionally low AMH level of 0.4 ng/mL possesses low egg numbers, yet those few oocytes retain the high chromosomal euploidy rates characteristic of her chronological age. Conversely, a 43-year-old female with an AMH of 2.5 ng/mL possesses abundant follicles, yet the overwhelming majority will be meiotically aneuploid, resulting in reduced natural conception rates and elevated spontaneous miscarriage frequencies. Chronological age, not AMH, remains the primary determinant of oocyte quality.
• Intra-individual and Assay Variability: While significantly more stable than other reproductive hormones, systemic AMH levels are not invariant. Systemic inflammation, acute critical illness, body mass index (BMI) extremes, geographical variations, and prolonged exposure to hormonal suppression (such as depot medroxyprogesterone acetate or combined oral contraceptive pills) can suppress observed values, causing diagnostic misclassifications if retesting is not conducted after cessation.
• Inability to Pinpoint Exact Menopausal Timing: Although an undetectable AMH value indicates impending reproductive exhaustion, it cannot reliably predict the exact month or year when clinical menopause (the cessation of menses for 12 consecutive months) will arrive, due to stochastic variations in the survival of the terminal follicular pool.

14. Related Terms & Distinctions

To avoid diagnostic ambiguities, AMH must be contrasted with closely allied reproductive hormones and diagnostic modalities:

• Antral Follicle Count (AFC): An ultrasound evaluation performed via transvaginal imaging that visually enumerates the physical follicles measuring 2–10 mm within both ovaries during the early follicular phase. While AFC and AMH display strong clinical correlation, AFC is dependent on modern ultrasonographic equipment and skilled operator performance, whereas AMH offers an objective, operator-independent laboratory assessment.
• Follicle-Stimulating Hormone (FSH): A gonadotropin synthesized by the anterior pituitary gland that stimulates follicular growth. Unlike AMH, peripheral FSH concentrations exhibit massive cyclical fluctuations, rising steeply in the early follicular phase as estrogen drops and peaking at mid-cycle. High basal early follicular FSH (> 10–15 IU/L) indicates diminished reserve, but FSH operates via an indirect negative feedback loop, making it less sensitive and late-responding compared to the direct ovarian synthesis of AMH.
• Estradiol ($E_2$): The principal biological estrogen secreted by pre-ovulatory mature dominant follicles and the corpus luteum. Estradiol mirrors the functional maturation of selected, late-stage follicles, whereas AMH marks the baseline reservoir of immature, unrecruited follicles.
• Inhibin B: A dimeric peptide produced by growing preantral and early antral follicles that directly feeds back to suppress pituitary FSH secretion. While historically utilized as an ovarian marker, Inhibin B demonstrates marked cyclicity across the menstrual cycle, rendering it clinically inferior to AMH as a stable, primary ovarian biomarker.

15. Summary / Key Takeaways

Anti-Müllerian hormone is a multifunctional dimeric glycoprotein that serves two fundamental biological functions across the human lifespan: driving anatomical embryonic sexual differentiation in genetic males, and acting as an indispensable gatekeeper and clinical proxy of ovarian reserve in adult females. By regulating follicular entry into the active growing pool and attenuating FSH sensitivity, AMH preserves ovarian longevity. While modern automated assays have established AMH as the gold standard for predicting oocyte yields during assisted reproductive technologies and for corroborating polycystic ovary syndrome, it must not be misconstrued as an indicator of natural, unassisted conception rates or a measure of oocyte chromosomal quality. Integrated within comprehensive, evidence-based diagnostic frameworks, AMH remains one of the most powerful diagnostic markers in modern endocrinological medicine.

References

• Broekmans, F. J., Kwee, J., Hendriks, D. J., Mol, B. W., & Lambalk, C. B. (2006). A systematic review of tests predicting ovarian reserve and ovarian response in IVF cycles. Human Reproduction Update, 12(6), 685–718. https://doi.org/10.1093/humupd/dml034
• Dewailly, D., Andersen, C. Y., Balen, A., Broekmans, F., Dilaver, N., Fanchin, R., Griesinger, G., Kelsey, T. W., La Marca, A., Lambalk, C., Mason, H., Nelson, S. M., Visser, J. A., Wallace, W. H., & Anderson, R. A. (2014). The physiology and clinical utility of anti-Müllerian hormone in women. Human Reproduction Update, 20(3), 370–385. https://doi.org/10.1093/humupd/dmt062
• Jost, A. (1947). Recherches sur la différenciation sexuelle de l’embryon de lapin. Archives d’Anatomie Microscopique et de Morphologie Expérimentale, 36, 271–315.
• Nelson, S. M. (2013). Biomarkers of ovarian response: Current and future applications. Fertility and Sterility, 99(4), 963–969. https://doi.org/10.1016/j.fertnstert.2012.11.051
• Steiner, A. Z., Pritchard, D., Stanczyk, F. Z., Kesner, J. S., Meadows, J. W., Herring, A. H., & Baird, D. D. (2017). Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA, 318(14), 1367–1376. https://doi.org/10.1001/jama.2017.14588
• Tata, B., Mimouni, N. E. H., Barbotin, A. L., Malone, S. A., Loyens, E., Pigny, P., Dewailly, D., Catteau-Jonard, S., & Giacobini, P. (2018). Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nature Medicine, 24(6), 834–846. https://doi.org/10.1038/s41591-018-0031-5
• Visser, J. A., de Jong, F. H., Laven, J. S., & Themmen, A. P. (2006). Anti-Müllerian hormone: A new marker for ovarian function. Reproduction, 131(1), 1–9. https://doi.org/10.1530/rep.1.00529